- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Erratum to: Dual HER2 blockade: preclinical and clinical data ; volume:16 ; number:6 ; day:6 ; month:11 ; year:2014 ; pages:1-2 ; date:12.2014
Breast cancer research ; 16, Heft 6 (6.11.2014), 1-2, 12.2014
- Urheber
-
Patel, Tejal A.
- Beteiligte Personen und Organisationen
-
Dave, Bhuvanesh
Rodriguez, Angel A.
Chang, Jenny C.
Perez, Edith A.
Colon-Otero, Gerardo
SpringerLink (Online service)
- DOI
-
10.1186/s13058-014-0468-9
- URN
-
urn:nbn:de:1111-2016032421414
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Patel, Tejal A.
- Dave, Bhuvanesh
- Rodriguez, Angel A.
- Chang, Jenny C.
- Perez, Edith A.
- Colon-Otero, Gerardo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Dual HER2 blockade: preclinical and clinical data
Die duale HER2-Blockade : Grundlagen und Perspektiven beim Mammakarzinom
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts
Efficacy and safety of dual blockade of HER2 and PD-1 in patients with HER2-positive gastric cancer: a retrospective, multicentre study
Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis
De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China
Erratum to: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Preclinical research progress in HER2-targeted small-molecule probes for breast cancer
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
Dual HER2 blockade: preclinical and clinical data
Die duale HER2-Blockade : Grundlagen und Perspektiven beim Mammakarzinom
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts
Efficacy and safety of dual blockade of HER2 and PD-1 in patients with HER2-positive gastric cancer: a retrospective, multicentre study
Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis
De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China
Erratum to: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Preclinical research progress in HER2-targeted small-molecule probes for breast cancer
Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
Dual HER2 blockade: preclinical and clinical data
Die duale HER2-Blockade : Grundlagen und Perspektiven beim Mammakarzinom
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade
Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts
Efficacy and safety of dual blockade of HER2 and PD-1 in patients with HER2-positive gastric cancer: a retrospective, multicentre study
Comparison of neoadjuvant single-agent treatment and dual-HER2 blockade for breast-conserving surgery conversion in HER2-positive breast cancer: a meta-analysis
De-escalation of neoadjuvant taxane and carboplatin therapy in HER2-positive breast cancer with dual HER2 blockade: a multicenter real-world experience in China
Erratum to: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Preclinical research progress in HER2-targeted small-molecule probes for breast cancer